Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | CSF1R | P07333 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 6/20 | 0.33 |
| ▸ | RAB9A | P51151 | 6/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.33 |
| ▸ | CCNC | P24863 | 1/20 | 0.33 |
| ▸ | CDK8 | P49336 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 4/20 | 0.33 |
| ▸ | FEN1 | P39748 | 4/20 | 0.33 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30467645 | 1.00 | TSHR (0.34) | TSHRRECQLCSF1RMTORNPC1 | |
| SCHEMBL26771345 | 0.92 | MTOR (0.35) | TSHRRECQLCSF1RMTORNPC1 | |
| SCHEMBL24252672 | 0.82 | FEN1 (0.36) | POLBFEN1LMNAALDH1A1HTT | |
| Formic Acid SCHEMBL25250167 | 0.80 | FEN1 (0.33) | POLBFEN1 | |
| Formic Acid SCHEMBL30467631 | 0.80 | FEN1 (0.33) | POLBFEN1 | |
| SCHEMBL24252356 | 0.80 | ALOX5AP (0.36) | ALOX5APFEN1 | |
| Formic Acid SCHEMBL30467670 | 0.77 | ALOX5AP (0.35) | ALOX5APFEN1 | |
| Formic Acid SCHEMBL25250023 | 0.77 | ALOX5AP (0.35) | ALOX5APFEN1 | |
| SCHEMBL24252619 | 0.77 | PDE10A (0.40) | RECQLNPC1POLBLMNAALDH1A1 | |
| SCHEMBL25840702 | 0.77 | PLG (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260070932-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-12509474-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-20240109920-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2024-04-04 | — | — | US | disclosed |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| EP-4185592-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | Annexon, Inc. (US) | 2023-05-31 | — | — | EP | disclosed |
| US-20220048930-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2022-02-17 | — | — | US | disclosed |
| US-20220048930-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109920-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFB, CFH, C9 | TSHR 2377/4885RECQL 860/4885CSF1R 963/4885 |
| US-20220048930-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFB, CFH, C9 | TSHR 2377/4885RECQL 860/4885CSF1R 963/4885 |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | CFB, CFH, C9 | TSHR 2377/4885RECQL 860/4885CSF1R 963/4885 |
| US-12509474-B2 | Inhibitors of complement factors and uses thereof | SSB, UACA, CFH | TSHR 437/4885RECQL 844/4885CSF1R 3790/4885 |
| US-20260070932-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFH, CFB, C5 | TSHR 204/4885RECQL 1293/4885CSF1R 2823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.